SPECIAL REPORT: How Will the Withdrawal of Generic Albuterol Change the U.S. Respiratory Disease Market?

Published Date: June 2007 Published By: Decision Resources Page Count: 29 Order Code: R55-364 $2,250.00   PDF E-mail From Publisher $4,500.00   Global Site License Fulfilled by Publisher   Questions About This Report E-mail a Colleague Printable Page Fax Your Order Description Table of Contents Similar Products Executive Summary Strategic Considerations Stakeholder Implications Introduction The Montreal Protocol Respiratory Diseases An Overview of Asthma Disease Defi nition, Etiology, and Prevalence Treatment of Asthma An Overview of Chronic Obstructive Pulmonary Disease Disease Defi nition, Etiology, and Prevalence Treatment of COPD Use of Symptomatic Bronchodilators in the Treatment of Asthma and COPD The Respiratory Disease Market Controller Agents Reliever Agents The Albuterol Market in the United States Challenges of the Switch to HFA Formulations Demand and Manufacturing Concerns Manufacturer Compliance Lack of Equivalence Reimbursement Issues Market Outlook Demand for Albuterol Competitive Threats U.S. Market Forecast Winners and Losers Appendix A. Market Forecast Scenarios for Branded HFA Products in the United States, 2006-2011 Methodology and Assumptions Drug-Treated Population Treated Days and Compliance Price per Patient per Year Scenario 1: Proventil HFA Takes Early Market Leadership Scenario 2: Competitive Pricing Scenario 3: Physicians Choose to Switch Patients to Xopenex Tables 1. Prevalent Cases of Asthma and COPD, 2006 2. Sales of Leading Agents to Treat Asthma and COPD, 2006 3. Forecasted Sales of Reliever Agents in the United States, 2008 and 2011 A. Combined Asthma and COPD Drug-Treated Populations in the United States, 2006-2011 B. Annual Cost of HFA Agents for a Single Patient Figures 1. Sales of Albuterol, 1986 - 2006 2. Sales of Albuterol in the United States, 2000-2006 A. Sales of Short-Acting Beta2 Agonists (Scenario 1: Proventil Takes Early Market Leadership), 2006-2011 B. U.S. Market Shares, 2011 (Scenario 1: Proventil Takes Early Market Leadership) C. Sales of Short-Acting Beta2 Agonists (Scenario 2: Competitive Pricing), 2006-2011 D. U.S. Market Shares, 2011 (Scenario 2: Competitive Pricing) E. Sales of Short-Acting Beta2 Agonists (Scenario 3: Physicians Switch Patients to Xopenex), 2006-2011 F. U.S. Market Shares, 2011 (Scenario 3: Physicians Switch Patients to Xopenex) Sidebars Barriers to Entry:What Is Discouraging Companies from Developing Albuterol? How Will Albuterol Manufacturers Differentiate Their Products? Similar Products • Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 Published Nov 2009 by Wintergreen Research • The Future of the Diabetes Care Devices Market to 2015 Published Nov 2009 by Global Markets Direct • Cooper Companies Medical Device Company Intelligence Report Published Oct 2009 by Espicom Healthcare Intelligence • Abbott Medical Device Company Intelligence Report Published Oct 2009 by Espicom Healthcare Intelligence • Invacare Medical Device Company Intelligence Report Published Oct 2009 by Espicom Healthcare Intelligence • Boston Scientific Medical Device Company Intelligence Report Published Oct 2009 by Espicom Healthcare Intelligence • Teleflex Inc. - SWOT Analysis Published Oct 2009 by Datamonitor